PharmTech Drug Digest 11.20
News|Articles|November 17, 2026

Giredestrant Takes ESR1 Breast Cancer Treatment Into Oral Solid Doses

Listen
0:00 / 0:00

Key Takeaways

  • FDA cleared giredestrant plus everolimus for ESR1-mutated ER-positive/HER2-negative advanced breast cancer, contingent on an FDA-authorized assay and prior endocrine exposure in adjuvant or metastatic settings.
  • Phase 3 evERA in post–CDK4/6 inhibitor disease showed significantly improved PFS with giredestrant/everolimus versus endocrine therapy/everolimus (HR 0.38; P < .0001).
SHOW MORE

The FDA approves oral SERD giredestrant for ESR1-mutated breast cancer after a 62% risk cut, tying supply to testing ahead of a Nov. 30 adjuvant decision.

The FDA has approved Roche’s Wilserdly (giredestrant) in combination with everolimus for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer.1 The approval covers patients whose ESR1 mutation is identified by an FDA-authorized test and whose disease came back during or after endocrine-based adjuvant therapy, or progressed on at least 1 endocrine-based regimen in the metastatic setting.

Giredestrant is an oral selective estrogen receptor degrader (SERD).1 It is designed to block estrogen binding and break down the ER protein. Up to 40% of patients with hormone receptor–positive metastatic breast cancer develop ESR1 mutations that drive endocrine resistance and disease progression.

What Did the evERA Trial Show?

The approval is based on the phase 3 evERA Breast Cancer study.2 The study enrolled patients with ESR1-mutated, ER-positive, HER2-negative disease that had progressed after prior cyclin-dependent kinase 4/6 inhibitor therapy. In those patients, giredestrant plus everolimus cut the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus (stratified hazard ratio, 0.38; 95% confidence interval, 0.27-0.54; P < .0001)

“For patients with ESR1-mutated advanced breast cancer, the development of resistance to endocrine therapy remains a substantial challenge - often requiring more intensive treatment,” said Levi Garraway, MD, PhD, chief medical officer, Roche, in a press release.1 “By pairing potent estrogen receptor degradation with everolimus, Wilserdly offers a targeted, all-oral regimen that significantly delays disease progression and allows advanced breast cancer patients to take their treatment from home.”

Why Does This Approval Matter?

The decision adds to a growing group of oral SERDs approved for patients selected by biomarker.1 In September, the FDA approved imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.3 The regulatory paths for these drugs have differed. In May, the agency extended its review of AstraZeneca’s camizestrant after an advisory committee did not reach a majority vote on the proposed strategy.4 That strategy calls for switching therapy when ESR1 mutations show up in circulating tumor DNA, before progression is visible on imaging.

Because the label requires an FDA-authorized test, uptake will depend on mutation testing being available alongside the drug supply.1 Because the regimen is all oral, treatment moves away from injections and into an oral solid-dose supply chain. Preclinical data showed improved potency vs other oral SERDs, which could allow one of the lowest doses in the class. That affects how much active pharmaceutical ingredient will be needed as the program grows.

“Patients with advanced breast cancer progressing on endocrine therapies often face difficult choices and deteriorating quality of life as options narrow,” said Erica L. Mayer, director of breast cancer clinical research, the Dana-Farber Cancer Institute, in the press release.1 “The evERA trial demonstrates that the oral giredestrant combination regimen directly targets the primary genomic drivers of resistance, offering patients prolonged disease control through a fully oral therapeutic option.”

What Comes Next for Giredestrant?

The FDA is also reviewing giredestrant under Priority Review as an adjuvant treatment for ER-positive, HER2-negative, stage I–III breast cancer at intermediate to high risk of recurrence.1 The application is based on the phase 3 lidERA study, and a decision is expected by Nov. 30, 2026. If the application is approved, giredestrant would be the first new adjuvant endocrine therapy in more than 20 years. Hormone receptor–positive, HER2-negative disease makes up approximately 70% of breast cancer cases, and more than 90% of those cases are diagnosed at an early stage.

How Is Roche Building Out Its Other Late-Stage Assets?

Alongside giredestrant, the FDA approved Roche’s Gazyva (obinutuzumab) on Nov. 16, 2026, as the first treatment for adults with primary membranous nephropathy, to induce remission of proteinuria.5 In the phase 3 MAJESTY study, 36.1% of adults achieved complete remission at 2 years with obinutuzumab vs 5.7% with tacrolimus (P < .001). Where giredestrant enters an oral solid-dose supply chain, obinutuzumab is a glycoengineered humanized monoclonal antibody, and this marks its third approval in immune-mediated kidney disease. With an FDA decision in systemic lupus erythematosus expected by December 2026, each new indication draws on an established biologic approved in 100 countries for hematological cancers.

References

  1. Roche. FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer. News release. November 16, 2026. Accessed November 17, 2026. https://www.roche.com/media/releases/med-cor-2026-11-16b
  2. Mayer EL, Tolaney SM, Martín M, et al. Giredestrant plus everolimus in advanced breast cancer. N Engl J Med. 2026;395(13):1285-1298. doi:10.1056/NEJMoa2602457 https://www.nejm.org/doi/full/10.1056/NEJMoa2602457?referrer=https%3A%2F%2Fwww.roche.com%2F
  3. Haigney S. Regulatory roundup—September 2026. Pharmaceutical Technology. October 2, 2026. Accessed November 17, 2026. https://www.pharmtech.com/view/regulatory-roundup-september-2026
  4. Zubulake Z. FDA delays AstraZeneca’s breast cancer drug review: what to know. PharmTech.com. May 27, 2026. https://www.pharmtech.com/view/what-to-know-about-fda-delaying-the-camizestrant-review
  5. Roche. Roche’s Gazyva/gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy. News release. November 16, 2026. Accessed November 17, 2026. https://www.roche.com/media/releases/med-cor-2026-11-16


Related to this article